No Data
No Data
Kangchen Pharmaceutical 2024 Semi-Annual Report
Summary of Kangchen Pharmaceutical\'s 2024 Semi-Annual Report
Beijing Konruns Pharmaceutical (603590.SH) released its performance for the first half of the year, with a net income of 79.2028 million yuan, a decrease of 14.73% compared to the same period last year.
Beijing Konruns Pharmaceutical (603590.SH) released its 2024 interim report, with the company achieving revenue of 4...
Beijing Konruns Pharmaceutical (603590.SH): net income in the first half of the year was 79.2028 million yuan, a decrease of 14.73% year on year.
On August 27th, Beijing Konruns Pharmaceutical (603590.SH) released its semi-annual report. From January to June 2024, the company achieved revenue of 405.0249 million yuan, a decrease of 10.16% compared to the same period last year. The net income attributable to the owners of the parent company was 79.2028 million yuan, a decrease of 14.73% compared to the same period last year. The net income attributable to the owners of the parent company, excluding non-recurring losses and gains, was 74.4971 million yuan, a decrease of 12.18% compared to the same period last year.
Beijing Konruns Pharmaceutical (603590.SH): Sun Yuping resigned from the position of secretary to the board and financial director.
Beijing Konruns Pharmaceutical (603590.SH) announced that the board of directors recently received a letter from Sun Yu, the secretary of the board of directors and the chief financial officer, stating that he is unable to continue to perform his duties due to personal reasons. The board of directors expressed their respect and understanding, and agreed to Mr. Sun's resignation.
Beijing Konruns Pharmaceutical (603590.SH): Clinical research results of the innovative traditional Chinese medicine ZY5301 made it into the sub-journal of JAMA.
On July 29, Gelonhui announced that ZY5301 is a traditional Chinese medicine innovative drug with independent intellectual property rights owned by Beijing Konruns Pharmaceutical Co., Ltd., focusing on the clinical research of chronic pelvic pain after female pelvic inflammatory disease. Recently, the Phase II clinical study results of ZY5301 (CTR20202153) were officially accepted and published in JAMANetworkOpen after rigorous evaluation by multiple international review experts.
No Data
No Data